515 related articles for article (PubMed ID: 15921377)
21. Conversion of tumors into autologous vaccines by intratumoral injection of α-Gal glycolipids that induce anti-Gal/α-Gal epitope interaction.
Galili U
Clin Dev Immunol; 2011; 2011():134020. PubMed ID: 22162709
[TBL] [Abstract][Full Text] [Related]
22. Natural killer cells license dendritic cell cross-presentation of B lymphoma cell--associated antigens.
Dao T; Gomez-Nunez M; Antczak C; Kappel B; Jaggi JS; Korontsvit T; Zakhaleva V; Scheinberg DA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8763-72. PubMed ID: 16361564
[TBL] [Abstract][Full Text] [Related]
23. L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies.
Chen W; Gu L; Zhang W; Motari E; Cai L; Styslinger TJ; Wang PG
ACS Chem Biol; 2011 Feb; 6(2):185-91. PubMed ID: 21043478
[TBL] [Abstract][Full Text] [Related]
24. Glycoengineering of alphaGal xenoantigen on recombinant peptide bearing the J28 pancreatic oncofetal glycotope.
Sadoulet MO; Franceschi C; Aubert M; Silvy F; Bernard JP; Lombardo D; Mas E
Glycobiology; 2007 Jun; 17(6):620-30. PubMed ID: 17374617
[TBL] [Abstract][Full Text] [Related]
25. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer immunotherapy using a tumor lysate vaccine, engineered to express α-gal epitopes, targets pancreatic cancer stem cells.
Tanida T; Tanemura M; Miyoshi E; Nagano H; Furukawa K; Nonaka Y; Akita H; Hama N; Wada H; Kawamoto K; Kobayashi S; Eguchi H; Mori M; Doki Y
Int J Oncol; 2015 Jan; 46(1):78-90. PubMed ID: 25354268
[TBL] [Abstract][Full Text] [Related]
27. Preparation of purified lymphoma cells suitable for therapy.
Lui G; Manches O; Chaperot L; Ducrot T; Molens JP; Sotto JJ; Bensa JC; Plumas J
Cytotherapy; 2004; 6(3):235-43. PubMed ID: 15203980
[TBL] [Abstract][Full Text] [Related]
28. Combination of cytokine-induced killer and dendritic cells pulsed with antigenic α-1,3-galactosyl epitope-enhanced lymphoma cell membrane for effective B-cell lymphoma immunotherapy.
Qiu Y; Yun MM; Dong X; Xu M; Zhao R; Han X; Zhou E; Yun F; Su W; Liu C; Zhao H; Tong X; Gao J; Ouyang X; Yun S
Cytotherapy; 2016 Jan; 18(1):91-8. PubMed ID: 26549382
[TBL] [Abstract][Full Text] [Related]
29. Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Galalpha1-3Galbeta1-4GlcNAc-R epitopes.
Abdel-Motal U; Wang S; Lu S; Wigglesworth K; Galili U
J Virol; 2006 Jul; 80(14):6943-51. PubMed ID: 16809300
[TBL] [Abstract][Full Text] [Related]
30. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
Mocikat R; Selmayr M; Thierfelder S; Lindhofer H
Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805
[TBL] [Abstract][Full Text] [Related]
31. A novel method to display [gal alpha1, 3 gal] antigens on human leukemic cells for preparation of anti-leukemia vaccines.
Posekany KJ; Wiley JE; Gagnon GA
Anticancer Res; 2009 Jun; 29(6):2387-92. PubMed ID: 19528506
[TBL] [Abstract][Full Text] [Related]
32. Natural protection from zoonosis by alpha-gal epitopes on virus particles in xenotransmission.
Kim NY; Jung WW; Oh YK; Chun T; Park HY; Lee HT; Han IK; Yang JM; Kim YB
Xenotransplantation; 2007 Mar; 14(2):104-11. PubMed ID: 17381684
[TBL] [Abstract][Full Text] [Related]
33. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
34. α1,3Galactosyltransferase knockout pigs produce the natural anti-Gal antibody and simulate the evolutionary appearance of this antibody in primates.
Galili U
Xenotransplantation; 2013; 20(5):267-76. PubMed ID: 23968556
[TBL] [Abstract][Full Text] [Related]
35. Accelerated healing of skin burns by anti-Gal/alpha-gal liposomes interaction.
Galili U; Wigglesworth K; Abdel-Motal UM
Burns; 2010 Mar; 36(2):239-51. PubMed ID: 19501971
[TBL] [Abstract][Full Text] [Related]
36. A possible role for the alpha 1-->3 galactosyl epitope and the natural anti-gal antibody in oncogenesis.
Gollogly L; Castronovo V
Neoplasma; 1996; 43(5):285-9. PubMed ID: 8996545
[TBL] [Abstract][Full Text] [Related]
37. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy.
Unfer RC; Hellrung D; Link CJ
Cancer Res; 2003 Mar; 63(5):987-93. PubMed ID: 12615713
[TBL] [Abstract][Full Text] [Related]
38. Dendritic cell viability is decreased after phagocytosis of apoptotic tumor cells induced by staurosporine or vaccinia virus infection.
Di Nicola M; Napoli S; Anichini A; Mortarini R; Romagnoli L; Magni M; Matteucci P; Baldassarri P; Bersani I; Carlo-Stella C; Gianni AM
Haematologica; 2003 Dec; 88(12):1396-404. PubMed ID: 14687994
[TBL] [Abstract][Full Text] [Related]
39. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
40. Mechanism for increased immunogenicity of vaccines that form in vivo immune complexes with the natural anti-Gal antibody.
Abdel-Motal UM; Wigglesworth K; Galili U
Vaccine; 2009 May; 27(23):3072-82. PubMed ID: 19428921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
